<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effect of delayed, prolonged systemic <z:mp ids='MP_0001845'>inflammation</z:mp> on <z:hpo ids='HP_0001297'>stroke</z:hpo> outcomes and <z:chebi fb="28" ids="17026">progesterone</z:chebi> (P4) neuroprotection in middle-aged rats </plain></SENT>
<SENT sid="1" pm="."><plain>After transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion (MCAO) surgery, rats received P4 (8 or 16mg/kg) or vehicle injections at 2h, 6h and every 24h until day 7 post-occlusion </plain></SENT>
<SENT sid="2" pm="."><plain>At 24h post-injury systemic <z:mp ids='MP_0001845'>inflammation</z:mp> was induced by giving three doses of <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS; 50μg/kg, at 4h intervals) to model post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We measured serum brain-derived neurotrophic factor (BDNF), pro-inflammatory cytokines, and behavioral parameters at multiple times </plain></SENT>
<SENT sid="4" pm="."><plain>Serum BDNF levels decreased more in the vehicle+LPS group compared to vehicle-alone at 3 and 7days post-injury (P&lt;0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Vehicle-alone showed a significant increase in interleukin-1β, interleukin-6, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha levels at different times following <z:hpo ids='HP_0001297'>stroke</z:hpo> and these levels were further elevated in the vehicle+LPS group </plain></SENT>
<SENT sid="6" pm="."><plain>P4 at both doses produced a significant (P&lt;0.05) decline in cytokine levels compared to vehicle and vehicle+LPS </plain></SENT>
<SENT sid="7" pm="."><plain>P4 restored BDNF levels at 3 and 7days post-<z:hpo ids='HP_0001297'>stroke</z:hpo> (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>Behavioral assessment (rotarod, grip strength, <z:e sem="disease" ids="C0751419" disease_type="Mental or Behavioral Dysfunction" abbrv="">sensory neglect</z:e> and locomotor activity tests) at 3, 5 and 7days post-<z:hpo ids='HP_0001297'>stroke</z:hpo> revealed that the vehicle group had significant (P&lt;0.05) deficits in <z:hpo ids='HP_0000001'>all</z:hpo> tests compared to intact controls, and performance was worse in the vehicle+LPS group </plain></SENT>
<SENT sid="9" pm="."><plain>P4 at both doses produced significant functional improvement on <z:hpo ids='HP_0000001'>all</z:hpo> tests </plain></SENT>
<SENT sid="10" pm="."><plain>Systemic <z:mp ids='MP_0001845'>inflammation</z:mp> did not show an additive effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> volume but P4 at both doses showed significant <z:mpath ids='MPATH_124'>infarct</z:mpath> reduction </plain></SENT>
<SENT sid="11" pm="."><plain>We suggest that post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> exacerbates <z:hpo ids='HP_0001297'>stroke</z:hpo> outcomes and P4 exerts neuroprotective/modulatory effects through its systemic anti-inflammatory and BDNF regulatory actions </plain></SENT>
</text></document>